ANI Pharmaceuticals Company Insiders

ANIP Stock  USD 55.86  0.76  1.38%   
ANI Pharmaceuticals' insiders are aggressively selling. The analysis of insiders' sentiment of trading ANI Pharmaceuticals stock suggests that virtually all insiders are panicking at this time. ANI Pharmaceuticals employs about 642 people. The company is managed by 13 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 49.38 employees per reported executive.
Stephen Carey  President
CFO, Vice President

ANI Pharmaceuticals' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-10-14Meredith CookDisposed 250 @ 57.19View
2024-09-13Meredith CookDisposed 250 @ 56.82View
2024-08-13Meredith CookDisposed 250 @ 59.62View
2024-07-17Muthusamy ShanmugamDisposed 14257 @ 63.16View
2024-07-15Muthusamy ShanmugamDisposed 11000 @ 63.38View
2024-07-12Meredith CookDisposed 250 @ 64.91View
2024-07-01Chad GassertDisposed 20000 @ 63.44View
2024-06-21Muthusamy ShanmugamDisposed 20000 @ 58.9View
2024-06-13Meredith CookDisposed 250 @ 63.8View
2024-06-05Ori GutwergDisposed 2985 @ 67View
2024-06-04Stephen P CareyDisposed 5000 @ 63.58View
2024-06-03Chad GassertDisposed 20000 @ 64.41View
2024-05-21Christopher MutzDisposed 2000 @ 61.61View
2024-05-20Muthusamy ShanmugamDisposed 12855 @ 61.81View
2024-05-17Muthusamy ShanmugamDisposed 5836 @ 62.09View
2024-05-16Renee P TannenbaumDisposed 2000 @ 63.87View
2024-05-15Muthusamy ShanmugamDisposed 14850 @ 65.86View
2024-05-14Nikhil LalwaniDisposed 16669 @ 66.1View
2024-05-13Meredith CookDisposed 250 @ 67.69View
2024-05-01Chad GassertDisposed 20000 @ 66.62View
Monitoring ANI Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

ANI Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ANI Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that ANI will maintain a workforce of slightly above 640 employees by December 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

ANI Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.0125 % which means that it generated a profit of $0.0125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.016) %, meaning that it created substantial loss on money invested by shareholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.07. At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 11/22/2024, Liabilities And Stockholders Equity is likely to grow to about 949.6 M, while Non Current Liabilities Other is likely to drop slightly above 14.4 M.
As of 11/22/2024, Common Stock Shares Outstanding is likely to grow to about 19.1 M, though Net Loss is likely to grow to (42.3 M).

ANI Pharmaceuticals Workforce Comparison

ANI Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 43,200. ANI Pharmaceuticals claims roughly 642 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.

ANI Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ANI Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ANI Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ANI Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.2759
8
29
 39,010 
 270,374 
2024-03-01
0.45
18
40
 332,173 
 288,803 
2023-09-01
0.1613
5
31
 38,118 
 605,824 
2023-06-01
0.6
6
10
 41,190 
 116,823 
2023-03-01
1.0588
18
17
 377,764 
 52,511 
2022-09-01
0.5
1
2
 19,280 
 8,818 
2022-06-01
2.75
11
4
 124,533 
 7,661 
2022-03-01
1.4286
10
7
 228,290 
 28,368 
2021-03-01
2.8
14
5
 372,563 
 7,829 
2020-06-01
1.1429
8
7
 141,744 
 7,552 
2020-03-01
0.3333
2
6
 5,000 
 9,932 
2019-06-01
0.2222
4
18
 6,154 
 58,150 
2019-03-01
1.3125
21
16
 187,656 
 82,851 
2018-09-01
1.0
1
1
 28,688 
 28,688 
2018-06-01
0.9474
18
19
 127,725 
 140,617 
2018-03-01
0.2813
9
32
 80,460 
 278,468 
2017-03-01
9.0
18
2
 138,125 
 1,120 
2016-12-01
1.0
2
2
 5,458 
 5,458 
2016-09-01
2.0
6
3
 106,356 
 50,791 
2016-06-01
7.0
21
3
 157,575 
 2,602 
2016-03-01
1.0
2
2
 22,446 
 22,446 
2015-12-01
1.5
3
2
 7,000 
 4,820 
2015-09-01
1.0
5
5
 38,561 
 38,561 
2015-06-01
3.0
24
8
 113,282 
 31,704 
2014-06-01
11.0
22
2
 352,182 
 6,381 
2014-03-01
0.3673
18
49
 142,326 
 423,664 
2013-12-01
1.2692
33
26
 264,442 
 91,104 
2013-09-01
2.4
24
10
 1,484,193 
 35,040 
2013-06-01
6.0
12
2
 42,096,523 
 283,883 
2009-12-01
6.0
12
2
 240,700 
 0.00 
2008-09-01
1.0
3
3
 147,512 
 147,512 

ANI Pharmaceuticals Notable Stakeholders

An ANI Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ANI Pharmaceuticals often face trade-offs trying to please all of them. ANI Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ANI Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nikhil LalwaniCEO PresidentProfile
Stephen CareyCFO, Vice PresidentProfile
Meredith CookGeneral VPProfile
Meredith JDGeneral VPProfile
Elizabeth JDChief DiseaseProfile
Krista DavisSenior OfficerProfile
Muthusamy RPhCOO RDProfile
Thomas RowlandSenior BrandsProfile
Chad GassertSenior StrategyProfile
James MarkenSenior DevelopmentProfile
Ori GutwergSenior GenericsProfile
Christopher MutzSenior DiseaseProfile
Mary MDChief OfficerProfile

About ANI Pharmaceuticals Management Performance

The success or failure of an entity such as ANI Pharmaceuticals often depends on how effective the management is. ANI Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ANI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ANI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.03  0.03 
Return On Capital Employed 0.06  0.07 
Return On Assets 0.02  0.02 
Return On Equity 0.04  0.05 

ANI Pharmaceuticals Workforce Analysis

Traditionally, organizations such as ANI Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ANI Pharmaceuticals within its industry.

ANI Pharmaceuticals Manpower Efficiency

Return on ANI Pharmaceuticals Manpower

Revenue Per Employee758.3K
Revenue Per Executive37.4M
Net Income Per Employee29.3K
Net Income Per Executive1.4M
Working Capital Per Employee583.1K
Working Capital Per Executive28.8M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.